The price of the lifesaving COVID-19 antiviral medication Paxlovid will more than double as the United States transitions out of the emergency phase of the pandemic.
The price of the lifesaving COVID-19 antiviral medication Paxlovid will more than double as the United States transitions out of the emergency phase of the pandemic, drugmaker Pfizer said Wednesday.The list price, before insurance, will be $1,390 for a five-day course, Pfizer said in a statement. That's 2.6 times higher than the $530-per-course price paid by the U.S. government, which provided Paxlovid free to patients during the pandemic.
transitions from a system in which the government purchased the medication and provided it free to everyone to a more traditional commercial marketplace. Paxlovid will continue to be free for patients through that system until the end of the year.COVID-19 vaccines also increased in price as they went through a similar transition to a commercial market, rising about fourfold to between $115 to $130 per dose.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
Pfizer to price COVID treatment Paxlovid at $1,390 per coursePfizer on Wednesday (PFE.N) said it will set the U.S. price for its COVID-19 antiviral treatment Paxlovid at nearly $1,400 per five-day course when it moves to commercial sales after government stocks run out.
Les mer »
Pfizer to price Covid drug Paxlovid at $1,390 per coursePaxlovid will transition to the private market in November, which comes as demand for Covid vaccines and treatments slumps nationwide.
Les mer »
Pfizer to price Covid drug Paxlovid at $1,390 per coursePaxlovid will transition to the private market in November, which comes as demand for Covid vaccines and treatments slumps nationwide.
Les mer »
Pfizer Prices Covid Drug Paxlovid at $1,400 for a Five-Day CourseDrugmaker is expected to offer steep discounts to ensure wide access
Les mer »
Pfizer Will Charge $1,390 For 1 Course Of COVID Drug Paxlovid On Commercial MarketNick Visser is a senior reporter on HuffPost’s breaking news team, covering the environment, U.S. politics and world news. Originally based in New York, he now lives in Sydney.
Les mer »
Pfizer and Moderna's updated COVID shots fully approved for people 12 and olderThe Pennsylvania Breast Cancer Coalition is celebrating 30 years.
Les mer »